Evaluation of a daptomycin dose-optimization protocol

American Journal of Health-System Pharmacy

Volumn 69, Issue 11, 2012, Pages 979-984

  Tran, Truc T ^a   Palmer, Hannah R ^b   Weston, Jaye ^c   Hirsch, Elizabeth B ^a   Shah, Dhara N ^a   Cottreau, Jessica ^a   Tam, Vincent H ^a   Garey, Kevin W ^a  

^a UNIVERSITY OF HOUSTON   (United States)

^b ST LUKE S EPISCOPAL HOSPITAL   (United States)

^c Baptist Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE KINASE; DAPTOMYCIN;

ARTICLE; CLINICAL PROTOCOL; CREATINE KINASE BLOOD LEVEL; CREATININE CLEARANCE; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG INDICATION; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; ENTEROCOCCAL INFECTION; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; VANCOMYCIN RESISTANT ENTEROCOCCUS;

EID: 84861476227     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp110279     Document Type: Article

References (25)

1. Murray BE. Vancomycin-resistant enterococcal infections. N Engl J Med. 2000; 342:710-21. (Pubitemid 30131425)
2. Hidron AI, Edwards JR, Patel J et al. NHSN annual update: antimicrobialresistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemiol. 2008; 29:996-1011.
3. Rossolini GM, Mantengoli E, Montagnani F et al. Epidemiology and clinical relevance of microbial resistance determinants versus anti-gram-positive agents. Curr Opin Microbiol. 2010; 13:582-8.
4. Sader HS, Jones RN. Antimicrobial susceptibility of gram-positive bacteria isolated from US medical centers: results of the Daptomycin Surveillance Program (2007-2008). Diagn Microbiol Infect Dis. 2009; 65:158-62.
5. Bhavnani SM, Drake JA, Forrest A et al. A nationwide, multicenter, case-control study comparing risk factors, treatment, and outcome for vancomycin-resistant and -susceptible enterococcal bacteremia. Diagn Microbiol Infect Dis. 2000; 36:14-58.
6. Enoch DA, Bygott JM, Daly ML et al. Daptomycin. J Infect. 2007; 55:205-13. (Pubitemid 47248484)
7. Malli E, Spiliopoulou I, Kolonitsiou F et al. In vitro activity of daptomycin against gram-positive cocci: the first multicentre study in Greece. Int J Antimicrob Agents. 2008; 32:525-8.
8. Louie A, Kaw P, Liu W et al. Pharmacodynamics of daptomycin in a murine thigh model of Staphylococcus aureus infection. Antimicrob Agents Chemother. 2001; 45:845-51. (Pubitemid 32182035)
9. Sader HS, Watters AA, Fritsche TR et al. Daptomycin antimicrobial activity tested against methicillin-resistant staphylococci and vancomycin-resistant enterococci isolated in European medical centers (2005). BMC Infect Dis. 2007; 7:29.
10. Critchley IA, Blosser-Middleton RS, Jones ME et al. Baseline study to determine in vitro activities of daptomycin against gram-positive pathogens isolated in the United States in 2000-2001. Antimicrob Agents Chemother. 2003; 47:1689-93. (Pubitemid 36548555)
11. Akins RL, Rybak MJ. Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother. 2001; 45:454-9. (Pubitemid 32105280)
12. Grim SA, Hong I, Freeman J et al. Daptomycin for the treatment of vancomycinresistant enterococcal infections. J Antimicrob Chemother. 2009; 63:414-6.
13. Gallagher JC, Perez ME, Marino EA et al. Daptomycin therapy for vancomycin-resistant enterococcal bacteremia: a retrospective case series of 30 patients. Pharmacotherapy. 2009; 29:792-9.
14. Moise PA, Herschberger E, Amodio-Groton MI et al. Safety and clinical outcomes when utilizing high-dose (≥8 mg/kg) daptomycin therapy. Ann Pharmacother. 2009; 43:1211-9.
15. White AC, Atmar RL, Wilson J et al. Effects of requiring prior authorization for selected antimicrobials: expenditures, susceptibilities, and clinical outcomes. Clin Infect Dis. 1997; 25:230-9. (Pubitemid 127775484)
16. Jasovich A, Curcio D, Caso Nunez H et al. Impact of the infectious disease team on the rationale for antibiotic usage: an expeditious intervention strategy which avoids limiting the physician's freedom. J Chemother. 2003; 15:409-11. (Pubitemid 36904329)
17. Curcio D, Belloni R. Strategic alliance between the infectious diseases specialist and intensive care unit physician for change in antibiotic use. J Chemother. 2005; 17:74-6. (Pubitemid 40463760)
18. Bryan CS. Strategies to improve antibiotic use. Infect Dis Clin North Am. 1989; 3:723-34.
19. Dunagan WC, Medoff G. Formulary control of antimicrobial usage. What price freedom? Diagn Microbiol Infect Dis. 1993; 16:265-74. (Pubitemid 23107312)
20. Cabana MD, Rand CS, Powe NR et al. Why don't physicians follow clinical practice guidelines? A framework for improvement. JAMA. 1999; 282:1458-65. (Pubitemid 29493800)
21. Mol PG, Wieringa JE, Nannanpanday PV et al. Improving compliance with hospital antibiotic guidelines: a time-series intervention analysis. J Antimicrob Chemother. 2005; 55:550-7. (Pubitemid 40542599)
22. Benvenuto M, Benziger DP, Yankelev et al. Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers. Antimicrob Agents Chemother. 2006; 50:3245-9. (Pubitemid 44527494)
23. Dvorchik BH, Brazier D, DeBruin MF et al. Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrob Agents Chemother. 2003; 47:1318-23. (Pubitemid 36368592)
24. Katz KE, Lindfield KC, Steenbergen JN et al. A pilot study of high-dose short duration daptomycin for the treatment of patients with complicated skin and skin structure infections caused by gram-positive bacteria. Int J Clin Pract. 2008; 62:1455-64.
25. Han SH, Chin BS, Lee HS et al. Vancomycin-resistant enterococci bacteremia: risk factors for mortality and influence of antimicrobial therapy on clinical outcome. J Infect. 2009; 58:182-90.